Chris Henstridge


Chris Henstridge
Postdoctoral Associate
Spires-Jones Lab
Tel: +44(0) 131 651 1884


Lab Webpage


Research Interests
Synaptic alterations feature in many neurological conditions and this has been a central focus throughout my postgraduate research. I spent my first postdoctoral position in the lab or Dr. Istvan Katona in Budapest, assessing the nanoscale distribution of synaptic proteins in a mouse model of Fragile X Syndrome, funded by an EMBO long-term fellowship. With the aim of building upon my imaging expertise, I recently moved to the lab of Dr. Tara Spires-Jones to learn the novel imaging technique, array tomography. This will be combined with electron microscopy to gain real insight into the underlying synaptic pathology in human neurological disorders such as Alzheimer’s Disease, Motor Neuron Disease and in general brain ageing.

Key Publications
Jung* KM, Sepers* M, Henstridge* CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D and Manzoni O. (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nature Communications3:1080 doi: 10.1038/ncomms2045  (* - equal contribution).
Henstridge CM. (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology. 89: 179-187.
Henstridge CM, Balenga NAB, Kargl JK, Andradas C, Brown AJ, Irving AJ, Sanchez C and Waldhoer M. (2011) Minireview: Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Molecular Endocrinology. 25: 1835-1848.
Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistle L, Kostenis E, Waldhoer M and Irving AJ. (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology 160: 604-614.
Henstridge CM, Balenga NAB, Ford LA, Ross RA, Waldhoer M. and Irving AJ. (2009) The GPR55 ligand L-α-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signalling and NFAT activation. FASEB Journal 23: 183-193.

Funding Sources
Alzheimer's Research UK